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Abbreviations 
ADC apparent diffusion coefficient 
ARRIVE animal research: reporting in vivo experiments 
BBB blood brain barrier 
DW-MRI  diffusion-weighted MRI 
EPI echo-planar imaging  
fBV fractional blood volume 
GBM glioblastoma (multiforme) 
H&E haematoxylin and eosin 
MGE multi gradient-recalled echo 
STR short tandem repeat 
IR-trueFISP inversion recovery true fast imaging with steady-state precession 
USPIO ultrasmall superparamagnetic iron oxide 
VEGF vascular endothelial growth factor 
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Abstract 
 
High grade and metastatic brain tumours exhibit considerable spatial variations in proliferation, 
angiogenesis, invasion, necrosis and oedema. Vascular heterogeneity arising from vascular co-
option in regions of invasive growth, in which the blood brain barrier remains intact, and 
neoangiogenesis is a major challenge faced in the assessment of brain tumours by conventional 
MRI. 
A multiparametric MRI approach, incorporating native measurements and both Gd-DTPA 
(Magnevist) and ultrasmall superparamagnetic iron oxide (USPIO, P904)-enhanced imaging was 
used, in combination with histogram and unsupervised cluster analysis using a k-means algorithm, 
to examine the spatial distribution of vascular parameters, water diffusion characteristics and 
invasion in intracranially propagated rat RG2 gliomas and human MDA-MB-231 LM2-4 breast 
adenocarcinomas in mice.  
Both tumour models presented with higher ∆R1 (the change in transverse relaxation rate R1 induced 
by Gd-DTPA), fractional blood volume (fBV) and apparent diffusion coefficient (ADC) than 
uninvolved regions of the brain. MDA-MB-231 LM2-4 tumours were less densely cellular than 
RG2 tumours and exhibited substantial local invasion, associated with oedema, whereas invasion in 
RG2 tumours was minimal. These additional features were reflected in the more heterogeneous 
appearance of MDA-MB-231 LM2-4 tumours on T2-weighted images and maps of functional MRI 
parameters.  
Unsupervised cluster analysis separated subregions with distinct functional properties; areas with a 
low fBV and relatively impermeable blood vessels (low ∆R1) were predominantly located at the 
tumour margins, regions of MDA-MB-231 LM2-4 tumours with relatively high levels of water 
diffusion and low vascular permeability and/or fBV corresponded to histologically-identified 
regions of invasion and oedema, and areas of mismatch between vascular permeability and blood 
volume were identified. 
4 
 
We demonstrate that dual contrast MRI and evaluation of tissue diffusion properties, coupled with 
cluster analysis, allows for the assessment of heterogeneity within invasive brain tumours and the 
designation of functionally diverse subregions that may provide more informative predictive 
biomarkers. 
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Introduction 
 
The effective treatment of brain tumours is an unmet and urgent clinical need. Five year survival for 
patients with grade IV glioma (glioblastoma, GBM) is only 5% (1); while patients with low-grade 
gliomas have a better prognosis, there is, as yet, no assured cure using conventional therapies. 
Patients with brain metastases, which affect approximately 8-10% of cancer patients, and 
approximately 30% of patients with breast cancer, have a similarly poor prognosis (2,3). High grade 
and metastatic brain tumours exhibit considerable spatial heterogeneity in gene expression and 
biochemistry, resulting in regional differences in tumour cell and microvascular proliferation, 
angiogenesis, necrosis and invasion. Diffuse infiltration of tumour cells in the neuropil, the dense 
network of interwoven neuronal and glial cell processes, is a characteristic of both low and high 
grade brain tumours (4), and whose clinical management is one of the greatest challenges facing 
neuro-oncologists and radiologists treating patients with brain tumours. 
 
Imaging biomarkers for the assessment of tumour pathophysiology and response to therapeutics are 
now widespread in the clinic and diagnostic imaging is an essential tool in the treatment 
stratification of patients with brain tumours. Magnetic resonance imaging (MRI) enables the 
visualisation of detailed anatomical features with high resolution due to its exquisite soft tissue 
image contrast (5) and is therefore the imaging methodology of choice for defining brain tumour 
anatomy and delineating tumours. Advanced MRI also provides a means of defining quantitative 
biomarkers to inform on biologically relevant structure-function relationships in tumours, enabling 
an understanding of the behaviour and heterogeneous distribution of such associations (6). There is 
a pressing need for refined MRI strategies and quantitative biomarkers to accurately interrogate 
specific growth patterns associated with infiltrative intracerebral tumours. 
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Conventional gadolinium-enhanced MRI, which is used extensively for diagnosis and staging, and 
in early stage clinical trials in solid tumours, relies upon the hyperpermeable nature of 
neoangiogenic tumour blood vessels. Infiltrating tumour cells in the brain obtain essential nutrients 
by co-opting the existing vasculature, leaving the blood brain barrier (BBB) intact, and 
consequently making appropriate delineation of infiltrative brain tumours problematic. 
Macromolecular ultrasmall superparamagnetic iron oxide (USPIO) particles, which remain within 
the vasculature over the duration of the MR imaging timeframe, have been used extensively pre-
clinically to delineate blood vessels and to provide estimates of fractional tumour blood volume and 
vessel calibre (7-9). USPIO-enhanced MRI, alone or in combination with gadolinium-enhanced 
MRI, may therefore enable delineation of vessels within glioma regions with an intact BBB within 
co-optive, infiltrative areas. 
 
We hypothesised that functional MRI, incorporating assessment of vascular parameters and 
diffusion characteristics, can report on heterogeneity within infiltrative brain tumours and inform on 
functionally diverse habitats. We employed a multiparametric MRI approach incorporating native 
measurements and both Gd-DTPA- and USPIO-enhanced imaging, and assessed the data using 
histogram and unsupervised cluster analysis, to examine the spatial distribution of vascular 
permeability and volume, diffusion characteristics and invasion in RG2 and MDA-MB-231 LM2-4 
intracranial tumours in vivo.  
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Materials and Methods  
 
Cell Culture 
RG2 rat glioma cells that stably express pGL4.50[luc2/CMV/hygro] (ATCC: Kind gift from Dr. D. 
Crichton, Cancer Research Technology, The Beatson Institute for Cancer Research, Glasgow. 
March 2010) and luciferase-expressing MDA-MB-231 LM2-4 highly malignant human triple 
negative breast adenocarcinoma cells derived from a lung metastasis from an orthotopic MDA-MB-
231 tumour (10) (provided by Dr. R. Kerbel, University of Toronto, Canada) were maintained in 
Dulbecco’s Modified Eagle’s Medium supplemented with 10% (v/v) foetal bovine serum (all 
Invitrogen, Life Technologies, Paisley, UK). Both cell lines tested negative for mycoplasma 
infection, and MDA-MB-231 LM2-4 cells were authenticated by short tandem repeat (STR) 
profiling, at the time of tumour propagation. 
 
Animals and Tumours 
All experiments were performed in accordance with the local ethical review panel, the UK Home 
Office Animals (Scientific Procedures) Act 1986, the United Kingdom National Cancer Research 
Institute guidelines for the welfare of animals in cancer research (11) and the ARRIVE (animal 
research: reporting in vivo experiments) guidelines (12). RG2 or MDA-MB-231 LM2-4 cells 
(5x103) were implanted supratentorially in the brains of 6 week old female athymic (NCr-Foxn1nu) 
mice (Charles River Ltd, Margate, UK), as previously described (13). A total of thirteen RG2 and 
fourteen MDA-MB-231 LM2-4 tumour bearing mice were used in this study. 
 
Bioluminescence Imaging 
Tumour establishment and growth was monitored by bioluminescence imaging using a Xenogen 
IVIS® 200 system coupled with LivingImage software (Caliper Life Sciences, Runcorn, UK). The 
luciferase substrate luciferin (150mg/kg, Caliper Life Sciences) was administered intraperitoneally 
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10 minutes before imaging. Total photon flux was established for automatically drawn regions of 
interest (ROIs) at a constant threshold. 
 
Magnetic Resonance Imaging 
1H magnetic resonance imaging (MRI) was performed on a 7T Bruker horizontal bore 
microimaging system (Ettlingen, Germany) using a 3cm birdcage coil and a 2.5cm x 2.5cm field of 
view. Anaesthesia was induced with a 10ml/kg intraperitoneal injection of fentanyl citrate 
(0.315mg/ml) plus fluanisone (10mg/ml (Hypnorm; Janssen Pharmaceutical Ltd. High Wycombe, 
UK)), midazolam (5mg/ml (Hypnovel; Roche, Burgess Hill, UK)), and sterile water (1:1:2). Both 
lateral tail veins were cannulated with a 27G butterfly catheter (Venisystems, Hospira, Royal 
Leamington Spa, UK) to enable the remote administration of Gd-DTPA (Magnevist™; Schering, 
Berlin, Germany; particle size <0.1nm) and USPIO particles (P904; Guerbet, Villepinte, France; 
particle size 25-30nm). Core body temperature was maintained by warm air blown through the 
magnet bore. 
Magnetic field homogeneity was optimised by shimming over the entire brain using an automated 
shimming routine (FASTMAP). A morphological, 20-slice, fast, multi-slice RARE spin-echo 
sequence was first used for localisation of the tumour and measurement of tumour volume. Next, 
diffusion-weighted (DW) images were acquired using an echo-planar diffusion-weighted (EPI-
DWI) sequence (TR=1500ms, TE=32ms, 10 b-values; b=0, 30, 60, 100, 150, 200, 300, 500, 750, 
1000s/mm2, 4 averages, 3x1mm slices). Subsequently, images were acquired from the same central 
slice using an inversion recovery (IR) true fast imaging with steady-state precession (trueFISP) 
sequence (TE=1.2ms, TR=2.4ms, scan TR=10s, TI=29-1930ms, 50 inversion times, 8 averages, 
matrix=128x128, 1x1mm slice, scan duration 10 minutes 40 seconds) prior to and 1 minute after 
administration of 0.1mmol/kg Gd-DTPA i.v. (Magnevist). Multi gradient-recalled echo (MGE) 
images (TR=1000ms, TE=6.2-31.1ms, 8 echoes, 2 averages, matrix=256x256, 9x1mm slices) were 
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acquired prior to and 2 minutes after intravenous administration of USPIO particles (150µmol 
Fe/kg, 8.38mg Fe/kg P904).  
 
MRI Data Analysis 
Parameter estimation was undertaken using a Bayesian maximum a posteriori algorithm, which 
took into account the Rician distribution of noise in magnitude MR data in order to provide 
unbiased parameter estimates (14,15). Estimates of the apparent diffusion coefficient (ADC, x10-6 
mm2 s-1) were determined from the EPI-DWI data. The dual relaxation rate sensitivity of the IR-
trueFISP sequence was utilised to provide estimates of both the native longitudinal and transverse 
relaxation times, T1 and T2 (ms). The change in R1 (=1/T1, ∆R1, s-1) following delivery of Gd-
DTPA was also evaluated. The transverse relaxation rate R2* (s-1) was quantified using the MGE 
data, and the USPIO-induced change in R2* (∆R2*) was used to estimate fractional blood volume 
(fBV, %), using the following equation (7,16):  
0
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Where ∆χ, the change in susceptibility induced by USPIO, was taken to equal 0.408 ppm, the 
Larmor frequency of protons (γ) taken to equal 4.26 × 107/s/T and the static magnetic field 
strength B0 = 7T. The value of ∆χ is valid for the dose of USPIO contrast agent used in vivo in mice 
(7). Pixels corresponding to a fBV exceeding 17% (the limit value for the linearity between ∆R2* 
and fBV (17)) were excluded. All data were fitted on a pixel-by-pixel basis using in-house software 
(ImageView, developed in IDL, ITT Visual Information Systems, Boulder, CO, USA), and the 
median value of each parameter determined from a region of interest (ROI) that encompassed the 
whole tumour. Where possible, ROIs were also drawn over an uninvolved region of the brain in the 
contralateral hemisphere to the injection of cells, on an imaging slice containing tumour, and the 
same analyses performed as for tumour ROIs. 
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Cluster Analysis  
Unsupervised cluster analysis was performed using in-house software developed in IDL. The K-
means algorithm was employed to partition the ROIs into sub-regions of similar characteristics, 
defined in the two-dimensional (2D) feature space formed by the two parameters ∆R1 and fBV,  
∆R1 and ADC, or fBV and ADC, and the three-dimensional (3D) feature space formed all three 
parameters (18). The optimal number of clusters for each dataset was determined using the cluster 
validation method described by Sugar and James (19).  
 
Histological Analysis 
Where possible, tumour bearing mice were administered with 15mg/kg of the perfusion marker 
Hoechst 33342 (Sigma-Aldrich, Poole, UK) intravenously through a lateral tail vein with the intact 
brain being rapidly excised one minute later, snap-frozen and stored in liquid nitrogen (20).  
Hoechst 33342 fluorescence signals were recorded at 365nm from whole frozen brain sections 
(10µm thick, three per tumour) using a motorised scanning stage (Prior Scientific Instruments, 
Cambridge, UK) attached to a BX51 microscope (Olympus Optical, London, UK), driven by CellP 
(Soft Imaging System, Münster, Germany). In addition, images of the tumour region only were 
acquired.  
The same sections were then stained with haematoxylin and eosin (H&E), and composite images 
were acquired using the same microscope system and co-ordinates under bright field illumination. 
These images were then used to draw tumour ROIs for analysis of the Hoechst 33342 data. 
Fluorescent particles were detected above a constant threshold, and the area of the tumour section 
with Hoechst 33342 fluorescence was determined and expressed as a percentage of the whole 
tumour area.  
The brains from the remaining mice bearing intracranial RG2 or MDA-MB-231 LM2-4 tumours 
(n=5 and n=4, respectively) were formalin-fixed and paraffin-embedded and 5µm sections were cut. 
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Sections from two levels through each tumour were stained with H&E, and cellular density assessed 
by counting the number of nuclei in four square ROIs with a side length of 50µm, resulting in a 
total area assessed of 0.01mm2 per field (200x magnification) (21). Three or more fields per section 
were assessed. 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, 
USA). Results are presented as the mean ± 1 standard error of the mean (s.e.m.), for imaging data 
the median value is taken for each tumour, and the cohort mean reported. Significance testing used 
Student’s unpaired or paired t-tests, where appropriate, with a 5% confidence level. Frequency 
histograms were produced (data acquired from all slices in individual animals and from all the 
animals in the cohort combined), and the degree of skew and kurtosis, were assessed. 
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Results 
 
A multiparametric MRI protocol, incorporating DW- and dual contrast enhanced MRI, was 
performed on mice bearing intracranially propagated rat RG2 glioma and human MDA-MB-231 
LM2-4 breast adenocarcinoma tumours. MRI was carried out when the tumour total photon flux 
reached a previously established threshold for each model representing a volume of approximately 
50mm3 (mean MRI-derived volume; RG2 47±12mm3, MDA-MB-231 LM2-4 53±7mm3, 22±0.2 
and 24±2.7 days post injection, respectively). Representative anatomical T2-weighted images and 
parametric maps of ADC, native T1 and T2, ADC, ∆R1 and fBV from each tumour model are shown 
in Figure 1a. The quantitative MRI data for tumour and uninvolved brain ROIs is summarised in 
Table 1. 
 
RG2 tumours revealed a more homogeneous appearance on T2-weighted MRI than MDA-MB-231 
LM2-4 tumours. Whilst both tumour models demonstrated heterogeneity in parametric functional 
MRI maps, the degree of heterogeneity appeared greater in MDA-MB-231 LM2-4 tumours. ADC 
was higher in both tumours than in uninvolved brain regions of the same animals. Histogram 
analysis revealed similar shaped distributions of ADC values in both tumour types, but with a shift 
towards higher values in the MDA-MB-231 LM2-4 data, resulting in a significantly higher median 
ADC (Figure 1b). Intracranial MDA-MB-231 LM2-4 tumours also exhibited significantly longer 
median T1 and T2 relaxation times, compared with orthotopic RG2 xenografts.  
 
Administration of Gd-DTPA increases the relaxation rate R1 in areas of brain tumours where the 
vasculature is permeable, for example in areas where the blood brain barrier is disrupted. The 
change in the tumour R1 (∆R1) following Gd-DTPA administration was significantly greater in 
MDA-MB-231 LM2-4 tumours than in RG2 tumours (Table 1). Insufficient ROIs could be drawn 
in uninvolved regions on the IR-trueFISP images in order to perform comparisons on paired 
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regions, but ∆R1 in both tumour types was significantly higher than that determined from 
uninvolved regions of both RG2 and MDA-MB-231 LM2-4-bearing brains. The frequency 
distribution of the combined uninvolved ROI data shows that ∆R1 values in these regions were 
spread over a narrower range at the lower end of the distribution of the tumour data, but there was 
no significant difference in skew or kurtosis between the individual ROI frequency distributions. 
 
Fractional blood volume (fBV) was significantly higher in both tumour models than in uninvolved 
regions of the brains of the same animals, and was significantly lower in MDA-MB-231 LM2-4 
tumours than RG2 tumours (Table 1). Frequency distributions revealed a lower occurrence of fBV 
values below approximately 7% in the tumour regions than the corresponding uninvolved regions of 
interest, a pattern seen to a lower extent between the MDA-MB-231 LM2-4 and RG2 tumours. The 
frequency distributions of ADC and fBV data in the uninvolved regions of mice bearing RG2 and 
MDA-MB-231 LM2-4 tumours were similarly shaped. 
 
H&E staining revealed that tumours derived from MDA-MB-231 LM2-4 cells grew as partially 
well circumscribed masses with substantial local invasion, principally occurring along existing 
blood vessels (Figure 2a, open head arrow), but also through the brain parenchyma. Tumours 
derived from RG2 cells grew as well circumscribed masses with limited areas of local invasion 
typically presenting as small groups of tumour cells or finger-like projections a small distance from 
the tumour border (Figure 2a). RG2 tumour cellularity was homogeneous and dense, whereas 
MDA-MB-231 LM2-4 tumours presented with regions of sparse cell density and oedema (Figure 
2a, closed head arrow). Quantitative analysis confirmed a significantly lower cellular density in 
MDA-MB-231 LM2-4 tumours (64±5 nuclei/0.01mm2) compared with RG2 tumours (82± 3 
nuclei/0.01mm2; p<0.05). Hoechst 33342 perfused area was assessed and quantified in MDA-MB-
231 LM2-4 and RG2 tumours (Figure 2b); no significant difference between the tumour types was 
observed. A positive and statistically significant correlation was determined between Hoechst 
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33342 perfused area and MRI derived fBV in the RG2 tumours with matched fBV and Hoechst 
33342 data (n=4, r2=0.93, p<0.05) but there was no significant relationship between fBV and 
Hoechst 33342 perfusion in the MDA-MB-231 LM2-4 tumours with matched data (n=5, r2=0.30, 
p>0.05).  
 
In order to assess the basis of the heterogeneity observed in intracranial tumours, particularly the 
more invasive MDA-MB-231 LM2-4, unsupervised cluster analysis was used to identify subregions 
with comparable functional parameters, and therefore similar biological properties, based on ∆R1, 
fBV and ADC. When applied to complete fBV datasets, the method identified an ‘outlier’ cluster of 
high fBV voxels (Supplementary Figure S1a). In order to eliminate this cluster and optimise the 
utility of the cluster analysis, a threshold was applied to each dataset, defined as the value below 
which a data point had only a 5% probability of belonging to the ‘outlier’ cluster, yielding 
thresholds of 21.2% for RG2 and 19.7% for MDA-MB-231 LM2-4 tumours. These values are in 
good agreement with the 17% threshold previously applied and reported by Troprès et al. (17), 
based on the observation that there is no longer linearity between ∆R2* and fBV above this value. 
Following this, the optimal number of clusters was then established as four for the 2D assessment of 
∆R1 and fBV in the RG2 tumours, and three for the 2D assessment of all pairs of parameters and the 
3D assessment of ∆R1, fBV and ADC together in MDA-MB-231 LM2-4 (19).  
 
Voxel distribution partitioned with the optimal number of clusters, cluster analysis colour maps of a 
representative tumour slice, and associated H&E images are shown in Figure 3. Figure S1b shows 
2D projections of the clustered 3D voxel distribution of all three parameters in MDA-MB-231 
LM2-4, providing a 2D view of the distribution for each parameter pair. In the maps of ∆R1 and 
fBV, red voxels indicative of areas with a low blood volume (low fBV) and relatively impermeable 
blood vessels (low ∆R1), were predominantly located at the tumour margins. Yellow voxels 
originate from subregions with a low blood volume but high vascular permeability. In the MDA-
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MB-231 LM2-4 tumours, all voxels with high fBV clustered together (blue voxels), irrespective of 
their relative vascular permeability, and were associated with the viable tumour mass. This cluster, 
driven by relatively high fBV, is also evident in cluster maps combining fBV with ADC and when 
the contributions from all three functional parameters are combined, although this is coupled with 
relatively high ∆R1. In RG2 tumours, however, these high fBV voxels were divided between those 
with low (blue) and high vascular permeability (green), and were heterogeneously distributed 
throughout the tumours.  
 
Cluster analysis maps of ∆R1 and ADC in the MDA-MB-231 LM2-4 tumours revealed yellow 
voxels with relatively high levels of water diffusion and low vascular permeability, and which 
largely corresponded to histologically-identified areas of invasion, vascular co-option and clear 
evidence of oedema (Figure 3c, closed head arrow). This subregion was also identifiable on cluster 
analysis maps of ADC and fBV, where high ADC coincides with low fBV and is clearly 
identifiable on the 3D analysis incorporating all three parameters. Red voxels with low vascular 
permeability but relatively restricted diffusion were associated with areas of invasion without 
oedema (Figure 3c, open head arrow), as were voxels ascribed to the red cluster with low fBV and 
low ADC. Blue voxels with higher ∆R1 and therefore higher vascular permeability, but with a range 
of ADC values, corresponded to the main dense cellular mass and largely corresponds to the red 
cluster in the three parameter maps corresponding to relatively low fBV, high ∆R1 and low ADC 
and the yellow cluster in maps incorporating fBV and ∆R1.  
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Discussion 
 
High grade and metastatic brain tumours exhibit considerable spatial variations in proliferation, 
cellularity, angiogenesis, invasion, necrosis and oedema. Recent publications have highlighted the 
potential value of spatial analysis of brain tumours, combining multiple MRI parameters to segment 
tumour from healthy tissue and to establish regional variations within tumours (22-25). Amongst 
the greatest challenges facing neuro-oncologists and radiologists treating patients with brain 
tumours is diffuse tumour cell infiltration and vascular co-option. In these regions the BBB remains 
intact, precluding detection by conventional Gd-DTPA-enhanced MRI. We therefore used 
multiparametric MRI, incorporating both Gd-DTPA and USPIO particle contrast agents, coupled 
with histogram and unsupervised cluster analyses, to evaluate the additional information that can be 
obtained regarding the underlying biology of intracranial tumours when the data acquired from 
sequences assessing tumour vascular permeability, blood volume and water diffusion are combined 
(18).  
 
A key issue at the outset of this study was the application of our multiparametric MRI strategy in 
intracranial tumour models displaying a clinically relevant invasive phenotype. RG2 rat glioma 
cells had previously been shown to display an infiltrative growth pattern and very limited 
extravasation of Gd-DTPA when propagated intracranially in mice (26). In our experience however, 
RG2 tumours consistently grew as relatively well circumscribed masses with limited local invasion 
that demonstrated signal enhancement following administration of Gd-DTPA, a phenotype 
consistent with the reported morphology of RG2 tumours grown in syngeneic Fischer 344 rats 
(27,28). Intracranial tumours derived from MDA-MB-231 LM2-4 cells, isolated from a lung 
metastasis following orthotopic implantation of MDA-MB-231 cells (10), which grow in a partially 
expansive, partially invasive manner (13) were therefore included in this study as a model of 
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invasive tumour growth in the brain. Intracranial injection of parental MDA-MB-231 cells has also 
been used to provide a model of metastatic brain disease (29). 
 
Interesting differences were apparent in the vascular phenotypes of the two tumour models studied. 
MDA-MB-231 LM2-4 tumours demonstrated higher ∆R1 than RG2 tumours, indicative of a higher 
degree of extravasation of contrast agent, hence more permeable vasculature. However, their fBV 
was lower than that of RG2 tumours, suggesting that, in the simplest terms, high vascular 
permeability does not necessarily correspond with high vascular density. Cluster analysis of fBV 
and ∆R1 allowed for these regions to be mapped spatially; those with low vascular density, but high 
vascular permeability (Figure 3b, yellow on ∆R1/fBV map, red on 3D cluster map), are likely 
indicative of regions of vasculogenesis, where sparse, immature permeable vessels are sprouting to 
provide a nutritive blood supply to the surrounding tumour cells (30). As expected, these regions 
were typically found within the principal tumour mass. Areas with low vascular volume and low 
vascular permeability (Figure 3b, red on ∆R1/fBV map) include those vessels that are not perfused, 
but may also correspond to areas with a low density of mature, relatively impermeable vessels, 
likely areas where the native vessels have been co-opted in regions of invasion (31). Indeed, these 
voxels, particularly in the MDA-MB-231 LM2-4 tumours, were predominantly located at the 
tumour margin, where tumour cell invasion was identified on H&E stained sections. Regions with 
high fBV had either more densely packed or larger calibre vessels, resulting in a relatively larger 
blood volume. Regions where both parameters were high, which only formed a separate cluster in 
the RG2 tumours (green), likely correspond to regions with either extensive neovasculature or large 
distended vessels (32).  
 
MRI protocols incorporating two vascular contrast agents, either an iron oxide preparation in 
combination with a gadolinium-based agent, or sequential injection of low and then high molecular 
weight gadolinium-based agents, performed either in the same imaging session or separated by 
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hours, have previously been used to assess tumour vasculature in intracranial tumour models in rats 
and mice (33-37), and for assessing response to anti-angiogenic treatment in melanoma xenografts 
in mice (38). The key advantage of the imaging strategy used herein is that it enabled the spatial 
analysis of how the vascular biomarkers assessed by the different contrast agents relate to each 
other, providing further insight into vascular phenotype and heterogeneity. 
 
Iron oxide based contrast agents such as P904 have been used extensively pre-clinically to assess 
tumour vascular architecture and function (39), but, to date, no iron oxide preparation has been 
approved for vascular imaging of patients with cancer. Recent studies have highlighted the off-label 
use of ferumoxytol (Feraheme®), an iron replacement therapy for patients with anaemia, as an 
intravenous MRI contrast agent (40). A number of clinical trials are underway, including the 
assessment of tumour vasculature in combination with gadolinium-based contrast agents in the 
same imaging session in adults with primary brain cancer or brain metastases, and in children with 
brain tumours (41). Studies such as these, which incorporate methods similar to those used in this 
study, may guide the creation of new imaging criteria/biomarkers to evaluate brain tumour 
progression and pseudo-progression secondary to radio-chemotherapy and anti-angiogenic agents. 
 
Susceptibility contrast MRI exploits negative contrast induced by USPIO particles, which 
inherently reduce signal-to-noise ratios (SNR). The Bayesian maximum a posteriori model used 
herein provides a thorough treatment of data point estimates of R2* involving representation of the 
associated uncertainties. For susceptibility contrast MRI it allows the determination of the 
significance of differences in R2* between two or more measurements, and consequently the 
probability that ∆R2* is greater than or less than zero on a pixel-by-pixel basis in vivo can be 
estimated (14). This method represents a more stringent calculation of MRI parameters when SNR 
is modest or low. Susceptibility artefacts as a result of the air-tissue interface can emerge in MGE 
images, but any data affected by such artefacts was excluded from analysis in this study.  
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We were interested to find that, whilst susceptibility contrast MRI–derived measurements of tumour 
fBV have previously been validated against uptake of the perfusion marker Hoechst 33342 (42) and 
a similar correlation was determined in the RG2 model herein, no such significant relationship was 
determined in the more invasive MDA-MB-231 LM2-4 tumours. We are pursuing further 
investigations into the pathological assessment of functional vasculature in invasive tumour models 
in order to understand this relationship more clearly. 
 
In addition to the assessment of tumour vasculature in the brain, the ability to assess cell density in 
brain malignancies using diffusion-weighted MRI is crucial, particularly where the permeability of 
the BBB is low. However, care must taken when interpreting ADC measurements, as the 
relationship between ADC and cell density can be complex, with relatively unrestricted diffusion in 
areas of oedema and necrosis offset by the reduced ADC in areas of increased cell density. Whilst 
neither model assessed in this study demonstrated significant necrosis, MDA-MB-231 LM2-4 
tumours demonstrated evidence of oedema and lower cell density compared to RG2 tumours. This 
was reflected in higher ADC and native T1 and T2 relaxation times, measures of the ratio of bound 
to free water in a tissue, reflecting increased extracellular space in the tumours (43). Histogram 
analysis of the distribution of ADC values further highlighted differences between tumour types, 
and compared with uninvolved regions of the brain. ADC values over 900x10-6mm2s-1 were rare in 
uninvolved brain regions, uncommon in RG2 tumours, but made up a significant proportion of 
MDA-MB-231 LM2-4 tumour voxels. These high ADC values represent the relatively unrestricted 
water diffusion in the areas of oedema observed on H&E stained MDA-MB-231 LM2-4 tumour 
sections that are absent from RG2 tumours. RG2 tumours were also more cellularly dense, 
consistent with the higher proportion of pixels with low ADC values (44). Interestingly, despite 
high cellular density and no oedema or necrosis, RG2 tumours had median ADC values and data 
distributions higher than the uninvolved brain. Assessment of cluster maps of MDA-MB-231 LM2-
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4 tumours incorporating ADC data, alongside H&E staining of the same tumours, revealed clusters 
of particular note driven by high ADC, denoting relatively unrestricted diffusion. These voxels 
displayed low ∆R1 and fBV (low vascular permeability and vascular volume) (Figure 3b, yellow 
cluster on all 2D and 3D maps including ADC), and corresponded to histologically confirmed 
regions of invasive tumour growth associated with oedema. A key imaging hallmark of brain 
tumours is an area of fluid-attenuated inversion recovery (FLAIR) or T2-weighted MRI 
hyperintensity outside the region of contrast enhancement, consisting of a combination of 
infiltrating tumour cells and oedema (45). The routine incorporation of diffusion-weighted imaging 
to gadolinium-enhanced imaging protocols in the clinic may thus assist in the more accurate 
resolution and characterisation of these brain tumour regions (46).  
 
Multiparametric MRI, focussing particularly on the microvasculature, was used by Coquery et al. to 
establish MRI-derived clusters to characterise tumour heterogeneity, and correlated them to 
pathophysiological features, in rat brain tumour models (25). 
MRI-based brain tumour segmentation to separate different tumour subcompartments from normal 
brain structures has been largely performed using supervised learning techniques, which are time 
consuming and expensive due to the requirement of teaching datasets and labelled images (47). 
Unsupervised methods are now increasingly being developed and have been shown to perform well 
in comparison to supervised techniques (24). Of particular importance is the segmentation of non-
enhancing tumour from healthy tissue to monitor tumour size more accurately over time (48).  
Further refinements in these techniques include 3D histogram analysis of routinely acquired images 
to identify radiologically-defined regional habitat variations in brain tumour data to provide deeper 
insight into the evolutionary dynamics of brain tumours (22), and the incorporation of quantitative 
functional parameters such as diffusion tensor imaging (DTI) and dynamic susceptibility contrast 
(DSC) MRI into machine learning algorithms, which identified complex and reproducible imaging 
patterns predictive of overall survival and molecular subtypes in glioblastoma (23). 
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In summary, intracranial implantation of MDA-MB-231 LM2-4 cells provides a useful model for 
the development of imaging biomarkers of the vascular and invasive phenotypes of tumours in the 
brain. We have demonstrated that multiparametric MRI, coupled with unsupervised cluster analysis, 
allows assessment of the patency of tumour vasculature by simultaneous assessment of both 
vascular permeability and tumour blood volume, potentially allowing delineation of vasculogenic 
regions and regions of co-opted normal brain vasculature. Spatial assessment of tissue diffusion 
properties in combination with vascular characteristics enabled the relationship between oedema 
and invasion/vascular co-option to be evaluated. Development and translation of such techniques 
that strengthen the links between in vivo imaging biomarkers and the structural and functional 
properties of tissue has the potential to provide predictive models to improve brain tumour 
diagnosis, prognosis and monitoring. 
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Figure Legends 
Figure 1  
a) T2-weighted MRI images and parametric maps of native T1 and T2 relaxation times, apparent 
diffusion coefficient (ADC), the change in relaxation rate R1 following intravenous administration 
of Gd-DTPA (∆R1), and fractional blood volume (fBV), from representative RG2 (upper panels) 
and MDA-MB-231 LM2-4 (lower panels) tumours propagated in the brain. b) Frequency 
histograms displaying the distribution of ADC, ∆R1 and fBV in RG2 and MDA-MB-231 LM2-4 
tumours, and uninvolved brain tissue (data from all evaluated ROIs). Sufficient data could not be 
acquired from matched uninvolved brain tissue for ∆R1 analysis, therefore values from brain tissue 
in tumour bearing mice where data could be assessed were combined (uninvolved). 
 
Figure 2  
a) Haematoxylin and eosin (H&E) staining of RG2 and MDA-MB-231 LM2-4; whole brain 
composite images and 100x images of the tumour periphery (middle panel) showed RG2 tumours as 
relatively well circumscribed masses with some local invasion at the periphery, and MDA-MB-231 
LM2-4 tumours as substantially locally invasive (open head arrow shows tumour cells surrounding 
a blood vessel) with associated oedema (closed head arrow). Right panel shows cell density at the 
centre of the tumours. Mean cellular density was assessed in both tumour types; MDA-MB-231 
LM2-4 tumours were significantly less dense. b) Fluorescence microscopy of Hoechst 33342 
uptake in representative RG2 and MDA-MB-231 LM2-4 tumour bearing brains revealed no 
significant difference between the perfused areas in the two tumour types. *p<0.05, unpaired 
Student’s t-test. 
 
Figure 3 
a) Cumulative distribution of voxels in the bi- or tri-dimensional space formed by two or three 
analysed parameters. Delta R1 (∆R1) and fractional blood volume (fBV) in RG2; ∆R1 and fBV, ∆R1 
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and apparent diffusion coefficient (ADC), fBV and ADC, and all three parameters in MDA-MB-
231 LM2-4 tumours. ∆R1 is expressed in units of x10-6ms-1, fBV in %, and ADC in units of 
×10−6mm2s-1. 2D projections of the clustered 3D voxel distribution are shown in Figure S1b. b) 
Corresponding cluster analysis maps of RG2 and MDA-MB-231 LM2-4 tumours; where data 
thresholding was applied, these values are removed from the maps. Voxels without an evaluable 
fBV (negative ∆R2*) are also missing from analyses incorporating fBV. c) H&E staining of the 
same tumours shows spatial relationships between cluster analysis maps and the tumour physiology. 
Closed head arrow denotes region of invasion along blood vessels and oedema, open head arrow 
denotes invasion without oedema, dashed arrow denotes main dense tumour mass. 
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 RG2 MDA-MB-231 LM2-4 RG2 uninvolved 
(n=6) 
MDA-MB-231 LM2-4 
uninvolved (n=7) 
Uninvolved         
(n=3) 
T1 (ms) 1278 ± 12   (n=5) 1402 ± 18 *** (n=7) - - 1227 ± 25 §§§ 
T2 (ms) 48.3 ± 1.3   (n=5) 58.3 ± 2.5 * (n=7) - - 41.9 ± 2.1 * §§ 
ADC (x10-6mm2s-1) 644 ± 16   (n=10) 811 ± 27 *** (n=8) 585 ± 9 # 576 ± 23 #### - 
∆R1 (x10-6ms-1) 246 ± 49   (n=5) 420 ± 46 * (n=6) - - 41 ± 8 * §§ 
fBV<17 (%)  6.8 ± 0.2   (n=13) 5.8 ± 0.3 ** (n=8) 4.0 ± 0.2 #### 4.4 ± 0.5 # - 
 
Table 1. Summary of the quantitative native and contrast-enhanced MRI biomarkers acquired in intracranially propagated RG2 and MDA-MB-
231LM2-4 tumours and uninvolved regions of tumour bearing brains.  
T1 = longitudinal relaxation time, T2 = transverse relaxation time, ADC = apparent diffusion coefficient, ∆R1 = change in the longitudinal relaxation 
rate R1 following intravenous administration of Gd-DTPA, fBV<17 = fractional blood volume with an upper threshold of 17%. Data are mean of median 
parameter values from each tumour. * p<0.05, ** p<0.01, *** p<0.001 vs RG2; §§ p<0.01, §§§ p<0.001, Student’s unpaired t-test; # p<0.05, #### 
p<0.0001 vs matched tumour ROIs, Student’s paired t-test. 
33 
 
34 
 
35 
 
36 
 
 
Supplementary Figure S1 
a) Cumulative distribution of voxels in the bi-dimensional space formed by delta R1 (∆R1, 
x10-6ms-1) and fractional blood volume (fBV, %) in RG2 and MDA-MB-231 LM2-4 without 
an upper threshold, showing the cluster distribution dominated by and ‘outlier cluster of high 
fBV values. Dashed line denotes threshold set as value at which a datapoint has only a 5% 
probability of belonging to the ‘outlier’ cluster. b) 2D projections of the clustered 3D voxel 
distribution of ∆R1, fBV, and ADC in MDA-MB-231 LM2-4 (Figure 3a), providing a 2D 
view of the distribution for each parameter pair. 
 
 
